Navigation Links
Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference

ontinuous release formulation of omega interferon with the Omega DUROS device may improve the treatment of HCV by offering a more convenient, potentially safer and more efficacious therapy for HCV patients."

About Omega DUROS Therapy

Omega DUROS therapy is being developed to improve the treatment of HCV by offering a more convenient and potentially safer and more effective treatment. Omega DUROS therapy is designed to deliver a continuous and consistent dose of omega interferon for three months via the implantable DUROS device, a drug delivery technology developed by ALZA Corporation, and licensed to Intarcia for use in certain broad fields. Another product incorporating the DUROS technology has already been approved by the FDA for the palliative treatment of prostate cancer. Intarcia is also leveraging the DUROS technology in evaluating other drug development opportunities. The most advanced of these is focused on the delivery of GLP-1 and GLP-1 analogs with the DUROS device for the treatment of type 2 diabetes.

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with chronic diseases in which there are significant unmet medical needs. Intarcia's drug development expertise and competitive edge are complemented by its ability to stabilize macromolecules and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. The initial programs that Intarcia is pursuing are in hepatitis C and type 2 diabetes.

About Hepatitis C

Hepatitis C is a major global public health problem. According to the World Health Organization, more than 170 million people worldwide are chronically infected with HCV, and three to four million new HCV infections occur annually. The U.S. Centers for Disease Control and Prevention has estimated that in the United States approximately 3.2 million people are chronically infected with HCV and approximately 25,00
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:4/27/2015)... , April 27, 2015 ... the addition of the "Endoscopy Global Market ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... approximately $43 billion by 2019 growing at around ... drivers for the market growth are aging population, ...
(Date:4/27/2015)... April 27, 2015  Eiger BioPharmaceuticals, Incorporated today announced ... of lonafarnib in patients with chronic hepatitis delta viral ... program, enrolled at Ankara University Medical School, ... endemic. LOWR HDV - 1 (LOnafarnib ... study which randomized subjects to receive different doses of ...
(Date:4/27/2015)... di Reggio Emilia, the Regional Health Service office for ... Zebra Technologies Corporation (NASDAQ: ZBRA ) wireless ... (WNS) provided by Zebra has allowed staff to ... via mobile computers, contributing to improved patient care with ... and guest Wi-Fi access and enables hospital staff to ...
Breaking Medicine Technology:Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 4Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 5
... Corporation (NYSE: SGP ) today reported that interim ... (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent ... virus (HCV) genotype 1. In the lead-in arms ... lead-in of PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) ...
... Sciences, Inc. (Nasdaq: CALP ), a leading provider of ... from the United States Food and Drug Administration (FDA) on ... screening and characterization assays for biological drugs. , "We were ... platform to a large group of reviewers. We believe the ...
Cached Medicine Technology:Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 2Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 4Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 5Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 6Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 7Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 8Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration 2
(Date:4/27/2015)... Clyde, NC (PRWEB) April 27, 2015 ... residents will conclude a social media campaign to raise ... and developer, Michael Mamas; and Sri Somesvara Temple. Ironically, ... Ridge Mountains of North Carolina, they thought they were ... commit to at least six months of meditation, service ...
(Date:4/27/2015)... 2015 Telematics Berlin is Europe’s biggest ... associations, CE players and the government to discuss the ... the car. This year’s panel on connected car security ... European Commission, is an opportunity to hear and contribute ... European Automotive Security Standard for years to come. ...
(Date:4/27/2015)... Chicago and its seven surrounding counties ... make area communities healthier, more sustainable and more beautiful. ... every five parkway trees likely to soon be destroyed ... this tree “tipping point,” Chicago-area residents are concerned, as ... Morton Arboretum . The Lisle, Illinois-based tree-focused institution’s Talking ...
(Date:4/27/2015)... The global coagulation analyzers market is estimated to ... however, it is expected to witness high growth ... Brazil in the next five years. Growth in ... such as increasing adoption of automated hemostasis instruments ... developments in high-sensitivity point-of-care coagulation analyzers and introduction ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 The Mount ... a seamless referral process for the Health System’s care ... heart failure or diabetes, for instance, may have more ... physicians coordinate with many other care providers. With medical ... of thousands of patients each year, the need for ...
Breaking Medicine News(10 mins):Health News:Mount Soma Monks Do Social Media 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 3Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 2Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 3Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 4Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 2Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 3Health News:Mount Sinai Launches System for Faster Referrals 2Health News:Mount Sinai Launches System for Faster Referrals 3
... A new study shows obesity may increase the risk ... by researchers at the National Institutes of Health, reveals ... adenocarcinoma than with squamous cell carcinoma. ,The study ... carcinoma, and 307 women without cancer as the control ...
... year, about 12,000 cases of cancer of the larynx are ... will have to have a laryngectomy// - taking away their ... new alternative that's giving patients their voices back. ,For ... no voice. "Some things you do not forget, and that ...
... to prevent bone loss may also help prevent prostate cancer ... United Kingdom indicates oral sodium clodronate may slow the spread ... death. //This is a drug commonly used to prevent bone ... in about 85 percent of men. The researchers recruited 311 ...
... done previously have shown that the hormone could suppress ... would not work in obese people because studies of another ... do a second trial to see if obese people were ... they are. They're just as sensitive as thin people." ...
... to eat healthier. A new study finds whole grains, fruits ... your overall risk of dying. However, the study also reports ... stroke. ,The U.S. Dietary Guidelines for Americans include choosing ... variety of grains daily, especially whole grains. While at least ...
... who suffer from asthma do not meet the right ... activity// of adults with asthma. Knowing if asthma patients ... health professionals in designing fitness programs for asthma patients. ... Prevention conducted a study to look at the physical ...
Cached Medicine News:Health News:A voice saving surgery 2Health News:Extra hormone found to cut appetite by a third 2
... compact system provides an ideal solution ... the laboratory, satellite lab and the ... staining method with wedge-smear technology, the ... standardization in a safe enclosed environment. ...
It is a cardio-pulmonary exercise testing device....
... Q-Stress Treadmill has digitally-controlled drive ... moving parts that can wear out. ... speed change mechanism, and fewer drive ... level of dependability. It can carry ...
... feature our internationally-acclaimed algorithm that is ... has a proven record for reliability ... and it's just one of several ... market leader in the stress testing ...
Medicine Products: